October 9-11, 2019
Hyatt Regency San Diego, CA, USA 





Ambrx®, Inc. is a clinical stage biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx® technology combines site-specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties.  The technology platform can optimize any protein or antibody to create best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates.

www. ambrx.com